Between Sept @ , @ , and July @ , @ , @ patients were randomly assigned , of whom five had a endoscopic subscore of @ or @ and were excluded from the mITT population , leaving @ patients in the etrolizumab @ mg group , @ in the etrolizumab @ mg plus LD group , and @ in the placebo group for the primary analyses .